Abstract
Background: Tuberculosis (TB) is threatening disease in China and new therapeutic agents and regimens to treat TB are urgently needed.
Objective: In this study, a DNA vaccine expressing Mycobacterium tuberculosis (MTB) Rv1419 antigen was constructed and its immunogenicity and therapeutic effects were evaluated. Method: Normal mice and TB model mice were immunized intramuscularly three times at two-week intervals with saline, plasmid vector pVAX1, M. vaccae vaccine, pVAX1- ag85a (rv3804c) DNA or pVAX1-rv1419 DNA, respectively. Results: At three weeks after the last immunization, flow cytometry showed a higher proportion of CD4+ T cells expressing IFN-γ (Th1) in response to Rv1419 protein in blood from the pVAX1- rv1419 DNA group compared with the saline and vector groups (P<0.05), suggesting a predominant Th1 immune response. Live bacterial loads in lungs and spleens were lower by 0.41 log10 in the pVAX1- rv1419 DNA group than in the saline controls. In addition, pathological changes in the lungs of the DNA vaccinated groups were less. These results suggest that pVAX1- rv1419 DNA could be effective for the treatment of TB, significantly increasing the Th1-type cellular immune response, and inhibiting the growth of MTB. Conclusion: Therefore pVAX1- rv1419 DNA is a candidate for inclusion in a therapeutic combination DNA vaccine against TB.Keywords: DNA vaccine, pVAX1-rv1419 DNA, Immunotherapy, Mycobacterium tuberculosis, Rv1419 protein, Immunization.
Current Gene Therapy
Title:Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis
Volume: 16 Issue: 4
Author(s): Yan Liang, Xiaoyan Zhang, Li Xiao, Xuejuan Bai, Xiaomei Wang, Yourong Yang, Junxian Zhang, Jinying Song, Yinping Liu, Ning Li and Xueqiong Wu
Affiliation:
Keywords: DNA vaccine, pVAX1-rv1419 DNA, Immunotherapy, Mycobacterium tuberculosis, Rv1419 protein, Immunization.
Abstract: Background: Tuberculosis (TB) is threatening disease in China and new therapeutic agents and regimens to treat TB are urgently needed.
Objective: In this study, a DNA vaccine expressing Mycobacterium tuberculosis (MTB) Rv1419 antigen was constructed and its immunogenicity and therapeutic effects were evaluated. Method: Normal mice and TB model mice were immunized intramuscularly three times at two-week intervals with saline, plasmid vector pVAX1, M. vaccae vaccine, pVAX1- ag85a (rv3804c) DNA or pVAX1-rv1419 DNA, respectively. Results: At three weeks after the last immunization, flow cytometry showed a higher proportion of CD4+ T cells expressing IFN-γ (Th1) in response to Rv1419 protein in blood from the pVAX1- rv1419 DNA group compared with the saline and vector groups (P<0.05), suggesting a predominant Th1 immune response. Live bacterial loads in lungs and spleens were lower by 0.41 log10 in the pVAX1- rv1419 DNA group than in the saline controls. In addition, pathological changes in the lungs of the DNA vaccinated groups were less. These results suggest that pVAX1- rv1419 DNA could be effective for the treatment of TB, significantly increasing the Th1-type cellular immune response, and inhibiting the growth of MTB. Conclusion: Therefore pVAX1- rv1419 DNA is a candidate for inclusion in a therapeutic combination DNA vaccine against TB.Export Options
About this article
Cite this article as:
Liang Yan, Zhang Xiaoyan, Xiao Li, Bai Xuejuan, Wang Xiaomei, Yang Yourong, Zhang Junxian, Song Jinying, Liu Yinping, Li Ning and Wu Xueqiong, Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis, Current Gene Therapy 2016; 16 (4) . https://dx.doi.org/10.2174/1566523216666161102170123
DOI https://dx.doi.org/10.2174/1566523216666161102170123 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecules of Infectious Agents as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Polyene Macrolide Antibiotic Biosynthesis
Current Medicinal Chemistry Medicinal Botanicals in the Traditional Medicine of the Veps Used for Bronchial Infections
Current Traditional Medicine Saccharomyces cerevisiae β-Carbonic Anhydrase: Inhibition and Activation Studies
Current Pharmaceutical Design Editorial (Thematic Issue: Nanotechnology for Drug Delivery: Part I)
Current Pharmaceutical Design Editorial (Thematic Issue: Molecular Determinants of Bacterial Diseases)
Current Medicinal Chemistry Combating Diseases with Computational Strategies Used for Drug Design and Discovery
Current Topics in Medicinal Chemistry Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Fighting Diabetes: Lessons from Xenotransplantation and Nanomedicine
Current Pharmaceutical Design Utility of Non-Conventional Applications of Anti-VEGF Treatment in Selected Retinal Diseases
Current Drug Therapy Invasive Aspergillosis in Children and Adolescents
Current Pharmaceutical Design Use of Anti-Infective Drugs in Rheumatology
Anti-Infective Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Current Medicinal Chemistry Molecular Modeling Used to Evaluate CYP2C9-Dependent Metabolism: Homology Modeling, Molecular Dynamics and Docking Simulations
Current Drug Metabolism Renal & Ocular Targets for Therapy in Wegeners Granulomatosis
Inflammation & Allergy - Drug Targets (Discontinued) The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors
Current Medicinal Chemistry Estimation of Affinity of HLA-A*0201 Restricted CTL Epitope Based on the SCORE Function
Protein & Peptide Letters Syntheses of Ethyl Pyruvate’s Bioisosteres Inhibiting Inducible Nitric Oxide Production in Lipopolysaccharide-induced BV2 Cells
Letters in Drug Design & Discovery Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Current Pharmaceutical Design Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry